Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE SULFATE versus NORMIFLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE SULFATE versus NORMIFLO.
ATROPINE SULFATE vs NORMIFLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine at parasympathetic postganglionic junctions. Increases heart rate, reduces exocrine secretions, relaxes smooth muscle in GI and GU tracts, and dilates pupils.
NORMIFLO is a selective alpha-1 adrenergic receptor antagonist that inhibits the binding of norepinephrine to alpha-1 receptors in the smooth muscle of the prostate and bladder neck, leading to relaxation of these muscles and improved urine flow.
0.5 to 1 mg intravenously or intramuscularly every 3 to 5 minutes as needed, up to a total of 3 mg (3 doses) for bradycardia; 0.5 to 1 mg subcutaneously, intramuscularly, or intravenously every 4 to 6 hours for antisecretory effects; 1 to 2 mg intravenously every 5 minutes for organophosphate poisoning.
Adults: 75 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life approximately 2-4 hours in adults; prolonged in elderly and infants; clinically significant due to potential accumulation with repeated dosing.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug and metabolites; ~50% excreted unchanged in urine; remainder as inactive metabolites (tropine, tropic acid); biliary/fecal excretion minor.
Renal excretion of unchanged drug accounts for 65-75% of elimination; biliary/fecal excretion accounts for 20-30%, with the remainder as metabolites.
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent